Aptevo Therapeutics Inc. Logo

Aptevo Therapeutics Inc.

Clinical-stage biotech developing antibody-based immunotherapies for cancer.

APVO | US

Overview

Corporate Details

ISIN(s):
US03835L2079
LEI:
Country:
United States of America
Address:
2401 4TH AVE., 98121 SEATTLE

Description

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company specializes in creating bispecific and trispecific antibody-based therapeutics designed to harness a patient's immune system to fight malignancies. Its pipeline includes multiple candidates targeting both hematologic cancers and solid tumors. The lead candidate, Mipletamig, is a CD3 T-cell engager targeting the CD123 tumor antigen for the treatment of Acute Myeloid Leukemia (AML). Other programs in development target various tumor antigens, including PSMA for prostate cancer and Nectin-4 for solid tumors, utilizing mechanisms like T-cell engagement and co-stimulation to enhance anti-tumor activity.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Aptevo Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptevo Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptevo Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genprex, Inc. Logo
Clinical-stage gene therapy company developing therapies for cancer and diabetes.
United States of America
GNPX
Genxone Spolka Akcyjna Logo
A biotechnology company specializing in Next Generation Sequencing and medical diagnostics.
Poland
GX1
GeoVax Labs, Inc. Logo
Clinical-stage biotech developing vaccines and therapies for infectious diseases and cancer.
United States of America
GOVX
GH Research PLC Logo
Develops mebufotenin-based therapies for psychiatric and neurological disorders.
United States of America
GHRS
GI Innovation Inc. Logo
Researches and develops protein-based drugs for immuno-oncology and immunology.
South Korea
358570
Ginkgo Bioworks Holdings, Inc. Logo
Operates a horizontal platform for cell programming and synthetic biology.
United States of America
DNA
GRAIL, Inc. Logo
A healthcare company developing blood tests for multi-cancer early detection.
United States of America
GRAL
GT Biopharma, Inc. Logo
Clinical-stage immuno-oncology company developing therapies with its NK cell engager tech.
United States of America
GTBP
Guard Therapeutics International AB Logo
Clinical-stage biotech developing therapies to prevent acute kidney injury.
Sweden
GUARD
Gubra A/S Logo
Biotech and CRO focused on peptide drugs for metabolic and fibrotic diseases.
Denmark
GUBRA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.